scholarly journals Acute Pancreatitis after Biliary and Pancreatic Stent Removal with a Forward-Viewing Endoscope

2021 ◽  
pp. 785-790
Author(s):  
Takeshi Okamoto ◽  
Katsuyuki Fukuda

Plastic biliary stents are commonly used for biliary drainage, while plastic pancreatic stents may be used prophylactically against acute pancreatitis in patients at high risk for post-endoscopic retrograde cholangiopancreatography pancreatitis. Removal of these prostheses is generally safe and can easily be performed in the ambulatory setting. Herein, we report a case of acute pancreatitis induced by removal of plastic biliary and pancreatic stents with a forward-viewing endoscope.

2015 ◽  
Vol 4 (2) ◽  
pp. 67-71
Author(s):  
Hossein Ajdarkosh ◽  
Gholamreza Hemasi ◽  
Farhad Zamani ◽  
Masoudreza Sohrabi ◽  
Mohammad Mahdi Zamani ◽  
...  

Background: Acute pancreatitis is a common complication of endoscopic retrograde cholangiopancreatography (ERCP). Several medical and surgical procedures have been analyzed in prevention of post-ERCP pancreatitis as a major post-ERCP complication, so we conducted a study to assess the role of prophylactic pancreatic stents on prevention and severity of post-ERCP pancreatitis. Materials and Methods: This case control studied adult patients undergoing ERCP at the ERCP unit of a referral educational hospital. Data of the case (stent, N=90) and control (non-stent) (N=105) groups were retrieved from medical records. In our center, sphinctrerotomy was performed for 103 patients of non-stent group and successful pancreatic stent placement was done in 86 patients of stent group in a standard fashion. In stent group, a 5F, 4 centimeter pancreatic stent was emplaced over a guide wire under fluoroscopic guidance. All post–ERCP pancreatitis and major complications of all patients were retrieved too. Results: Of 255 enrolled patients, 195 were at high risk of post-ERCP pancreatitis allocated in two groups of this study. Successful pancreatic stent placement was done in 86 patients (95.6%) of stent group. There was no major complication during procedures. The migration of pancreatic duct stent was diagnostic in 3 (3.5%) patients. The overall post ERCP pancreatitis was 4.0% and 16.6% in stent and non-stent groups, respectively. Conclusion: Based on our findings in this study, we strongly recommended pancreatic duct stent placement in high-risk patients; although the experience of endoscopist plays a crucial role. [GMJ.2015;4(2):67-71]


2021 ◽  
Vol 93 (6) ◽  
pp. AB151
Author(s):  
Vítor Macedo Silva ◽  
Marta Freitas ◽  
Rui S. Magalhães ◽  
Tiago Cúrdia Gonçalves ◽  
Pedro Boal Carvalho ◽  
...  

2018 ◽  
Vol 113 (Supplement) ◽  
pp. S444-S445
Author(s):  
Zubair Khan ◽  
Nauman Siddiqui ◽  
Mohamad Moussa ◽  
Muhammad Ali Khan ◽  
Thomas Sodeman ◽  
...  

2021 ◽  
Author(s):  
Zhaohui Deng ◽  
Biao Gong ◽  
Kaihua Yang ◽  
Jingqing Zeng ◽  
Chan Lv ◽  
...  

Abstract Background Acute pancreatitis is the most common complication of endoscopic retrograde cholangiopancreatography (ERCP) in children. To date, there is no suitable medicine for post-ERCP pancreatitis prophylaxis in children and few study has prospectively evaluated an intervention to prevent post-ERCP pancreatitis in children. Mirabilite, a well-known traditional Chinese medicine(TCM) has good therapeutic effects on acute pancreatitis and no side effect for children by basic research and clinical studies. Our protocol is designed to assess the efficacy and safety of the external use of mirabilite to prevent post-ERCP pancreatitis in children. Methods/design: 520 patients planned for diagnostic and therapeutic ERCP will be enrolled according to the eligibility criteria‎. The patients will be randomly divided into two equal groups (Mirabilite and control, the external use of mirabilite in a bag on the projected abdominal area over the pancreas within 30 min before ERCP). The primary end point is incidence of post-ERCP pancreatitis. Secondary end points include abdominal pain scores, the levels of inflammatory markers [tissue necrosis factor (TNF)-α, IL-6, and IL-8] and intestinal barrier function markers (diamine oxidase, D-lactic acid, and endotoxin). Additionally, the side effects of topical mirabilite is investigated. Conclusion This trial would be the first experiment to determine mirabilite to prevent post-ERCP pancreatitis in children. Mirabilite maybe provide potential clinical benefits and a new avenue with tremendous potential for the future preventing of post-ERCP pancreatitis. Trial registration number: ChiCTR1900022642. Registered on 19 April 2019- Retrospectively registered, http://www.chictr.org.cn.


2017 ◽  
Vol 85 (5) ◽  
pp. AB471
Author(s):  
Gabriela F. Paduani ◽  
Rafael Kemp ◽  
Jose Sebastiao S. dos Santos ◽  
Davi C. Aragon ◽  
Joao Guilherme G. Cabral ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document